Long-term efficacy of triptorelin 3-month depot in girls with central precocious puberty

Park, Kyu Hyun; Gwag, Si-Hwa; Kim, Yu Jin; Chung, Lindsey Yoojin; Kang, Eungu; Nam, Hyo-Kyoung; Rhie, Young-Jun; Lee, Kee-Hyoung

doi:.0.0.0

Ann Pediatr Endocrinol Metab > Accepted Articles

Original article

DOI: https://doi.org/10.6065/apem.2346132.066 [Accepted] Published online January 29, 2024.

Long-term efficacy of triptorelin 3-month depot in girls with central precocious puberty

Kyu Hyun Park¹

, Si-Hwa Gwag¹, Yu Jin Kim¹, Lindsey Yoojin Chung², Eungu Kang¹, Hyo-Kyoung Nam¹, Young-Jun Rhie¹, Kee-Hyoung Lee¹

¹Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
²Department of Pediatrics, Myoungji Hospital, Goyang, Korea

Address for correspondence: Kee-Hyoung Lee
Email: doclee@korea.ac.kr

Received: June 30, 2023 Revised: August 7, 2023 Accepted: August 26, 2023

Abstract

Purpose
Three-month gonadotropin-releasing hormone agonists (GnRHa) are expected to achieve better compliance in patients with central precocious puberty (CPP). However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.
Methods
In this retrospective study, 69 Korean girls with CPP were prescribed with either triptorelin pamoate (TP) 3-month depot (n = 29) or triptorelin acetate (TA) 1-month depot (n = 40) and were followed up for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.
Results
Baseline characteristics of the subjects were similar between the two groups. In the TP 3-month depot group, 27/29 (93.1 %) of patients exhibited suppressed LH levels (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8 ± 0.4 years at the start of treatment to 0.6 ± 0.5 years at 1 year post-treatment. The gain in predicted adult height (PAH) at 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2 ± 3.1 and 5.3 ± 2.4 cm, respectively; P = 0.875).
Conclusion
The 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For the patients’ convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.

Keywords: Central precocious puberty, Gonadotropin-releasing hormone, Triptorelin pamoate